Biomed Israel 2026 Preliminary Program
Ruti Alon, Founder and CEO, Medstrada
Ora Dar, PhD, Senior Expert, Medical Sciences and Health Innovation
Dr. Nissim Darvish, MD, PhD, Managing General Partner, Eliraz Ventures
Yair Schindel, MD, Chairperson, 8400 Health Network
Francois Maisonrouge, Senior Managing Director, Evercore Partners | A Turning Point in Life Sciences? What is Real? What is Not? What is Here to Stay?
Prof. Yifat Merbl, Professor of Immunology, Weizmann Institute of Science | Illuminating the Epiproteome: From Basic to Translational Research
Dr. Jeremy M. Levin, Phd, MD, Chairperson, Ovid Therapeutics and Opthea | Biotech in the Balance: Strategic Choices in a Multipolar World
HALL A
Beyond Bones and Screws: Rethinking Orthopedic Repair
Moderators
Dr. Adam L. Wollowick, MD, MBA, Advisor and Founder, Precision Life Sciences Partners
Dr. Assaf Dekel, MD, Chairman & CEO, OTS Medical
Keynote
Dr. Adam L. Wollowick, MD, MBA, Advisor and Founder, Precision Life Sciences Partners, Drivers of Value Creation in Recent Orthopaedic Transactions
Company Presenters
Yuval Mandelbaum, CEO, Discure, Discure – The First Disease-Modifying Therapy for Degenerative Disc Disease
Gil Hakim, CEO, Matricelf, Reconstructing the Injured Spinal Cord: Personalized Neural Tissue Engineering as the Next Frontier in Regenerative Medicine
Itzhak Mallayev, CEO, STFix, Sutureless, Load Distributing Platform for Rotator Cuff Repair Designed to Enhance Biomechanics and Support Biological Integration
Sahar Meiron, CEO, Orthotreat, Reprogramming Bone Healing: A Multi-Pathway Approach to Regeneration
Harel Manor, CEO, Fibioseq, Total Wrist Replacement – The Next Generation
Shmulik Shpiro, CEO, MRI2CT The MRI-Only Era 2.0
Ofer Levy, CEO, Zygofix, Anatomy Conforming Direct Facet Fixation for Spine and Pain
Orahn Preiss-Bloom, CEO, Ossio When Screws Become Bone: The Era of Biointegrative Orthopedics
HALL B
When Biology Becomes a Language: BioData Teaching
Moderator
Inbal Michailovici, Head of HealthTech, Israel Innovation Authority
Panel Moderator
Shai Melcer, PhD, Head of Bio-Convergence, Israel Innovation Authority
Panelists
Prof. Arie Admon, Academic Supervisor & Head of Academic committee, The Multi-Omics Center, Technion-Israel Institute of Technology
Prof. Adi Stern, Principal Investigator, Faculty of Life Sciences, Tel Aviv University
Prof. Michal Rosen-Zvi, Director of Healthcare and Life Sciences at IBM Research, IBM
Company Presenters
Dr. Isaac Bentwich, MD, CEO & Co-Founder, Quris
Tuvik Beker, PhD, CEO & Board Member, Pangea, Learning the Language of Cancer Response from Histopathology Images
Dr. Shai Shen-Orr,
Chief Scientist & Co-Founder, CytoReason, Professor; Technion – Israel Institute of Technology, Head; Laboratory of Systems Immunology & Precision Medicine, Director Zimin Institute for AI Solutions in Healthcare; Technion Healthy Aging Institute, CytoReason: Innovating AI for Biomed Impact
Eyal Betzalel, PhD, CTO & Co-Founder, Algocell, The Rise of Agentic AI in Bioprocess Modeling
HALL C
The Future of Aging: Where Longevity Meets Innovation
Moderators | Session Introduction
Anat Naschitz, Managing Partner, 9vc
Prof. Varda Shalev, MD, MPA, Managing Partner, Team8 Health
Dr. Pablo Cabral, MD, Executive Director, External Innovation, Eli Lilly and Company
Overview
Dr. Pablo Cabral, MD, Executive Director, External Innovation, Eli Lilly and Company
Keynote Speakers
Dr Uri Alon, Professor, Systems Biology and Director of the Sagol Institute for Longevity Research, Weizmann Institute of Science
Dr Abigail Goshen, Chief Scientific and Innovation Officer, Sheba Longevity Center, Translating Longevity Science into Longevity Medicine
Company Presenters
Haim Belinson, CEO, caVos Biotech Nature’s Longevity Code: Evolutionary mRNA Therapeutics to Combat Fibrosis and Extend
Healthspan
Effie Arditi, CEO, Longevitix, Next-Generation Preventive Care Where Longevity Science Meets Agentic AI
Ohad Gafni, CEO, RenewalBio, Stembroids – Pluripotent Stem Cell Differentiation Platform as a Novel Source for Patient Specific Transplantable Cells
David Reichman, CEO, Breeoot, ‘The window of opportunity – The most important health decisions you’ll ever make should be happening right now’ The decade before 60 determines the quality of every decade after it. The question isn’t whether to act, it’s whether you act in time.
Hillel Roth, PhD, Co-Founder & CSO, Aevum Labs The Power of Modeling Senescence
Ishay Attar, Chairman, CTO & Founder, BioChange Organ Regeneration with the Embryonic Foam of Life
Ganit Yarden, PhD, Head of R&D, Cellergy Therapeutics, Cellergy Therpeutics, Fueling the World with Human Energy
HALL A
The Device is No Longer a Device: Convergence in Medical Technology
Moderators
Eyal Lifschitz, Co-Founder & Managing General Partner, Peregrine Ventures
Dr. Irit Yaniv, MD, Founding Partner and CEO, Almeda Ventures
Eran Lerer, Managing Partner, Shoni Health Ventures
Company Presenters
Ben Omri, CEO & Co- Founder, Snipe Medical, Sparking New Hope for Lung Cancer Care
Daniel Ekeltchik, CEO & Co- Founder, ClearMargin, A New Treatment for Vessel Involving Tumors
Dr. Adrian Paz, MD, CEO & Co- Founder, Focal Medical, A New Approach to Focal Therapy for Prostate Cancer
Bar Evyatar, CEO & Co- Founder, Proventis, The Future of Male Contraception
Dr. David Shashar, MD, CEO, Pregnan Tech, Beyond the Device: Reimagining Preterm Birth Prevention
Edit Goldberg, DMD, CEO & Director, Escala Medical, Expanding the Horizon of Women’s Health: The First Solution for All Stages of POP
Shmuel Ben-Ezra, CEO, Nina Medical, A Paradigm Shift in the Treatment of the Enlarged Prostate: The Non-Invasive Era
Dr. Michal Gilon Ohev-Zion, Co-founder & CTO, Everly Bio, Everly Bio – How AI with Molecular Insights can Change the Fertility Journey
Dan Goldstaub, PhD, Head of Clinical Development, Xerient Pharma, Enhancing Radiation Therapy for Pancreatic Cancer Patients
Karny Ilan, PhD, CEO, Feminai, Reimagining Breast Cancer Detection from Home
Limor Halay, CEO, Femme Medical Redefining How Urinary Incontinence is Treated – Not Just Managed
HALL B
From Detection to Prediction: Successful Diagnostic Technologies and Business Models
Moderator
Yaron Daniely, PhD, General Partner, aMoon Fund
Overview of the Dx field in the last 2-3 years; an investors perspective
Keynote
A chat about building and exiting a Dx startup
Prof. Tomer Shlomi, Managing Director, MetaSight (Guardant Health Israel) in conversation with Yaron Daniely, PhD, General Partner, aMoon Fund
Audience Q & A
Company Presenters
Ronen Sadeh, CEO, Senseera, Progressing Liquid Biopsy into Decoding Transcriptional Programs from Cell-Free
Chromatin
Yael Schneidman, CEO, AccUrine
Ofer Bar On, Co-Founder & CEO, Luma Biophotonics Clinical Intelligence Platform for At-Home Chronic Disease Management
Manuela Vecsler, VP Clinical & Scientific Affairs, Ibex Medical Analytics Ibex AI-Powered Pathology: Driving Clinical Excellence and Accelerated Biomarker Development
Or Peleg, CEO, LiteBC
Anat Katz Arotchas, Chief Product Officer, PinkStar, Transforming Breast Cancer Detection with AI
Audience Q&A to presenters and moderators
HALL C
The Next Pandemic: Are We Ready? Innovation in Infectious Diseases
Moderator
Moshik Cohen-Kutner, PhD, Co-Founder and CEO, Omnix Medical
Keynote Speakers
Prof. Yehuda Carmeli, Director, National Center for Infection Prevention and Antibiotic Resistance, Ministry of Health, IL, Antibiotic Resistance: Health Burden, Diagnostic Gaps, and What We Can Do
Prof. Dimopoulos, Professor of Critical Care Medicine, University of Athens, Greece, The Clinician Perspective: Balancing Efficacy, Resistance, and Patient Outcomes
Company Presenters
Niv Bachnoff, PhD, CSO, Omnix Medical, Innovation in Sepsis: Can Antimicrobial Peptides Offer a New Therapeutic Approach?
Eran Eden, PhD, Co-Founder & CEO, MeMed, What If You Could Ask Your Immune System Any Question? From Idea to Patient Bedside in the AI Era
Saar Burshtein, former Commander of the laboratory division of IDF Medical Corps, Operational Microbiology in Crisis Zones: Rapid Laboratory Deployment in Field Hospital Settings
From Plague to Pandemic Preparation: mRNA-LNP Vaccines against Bacterial Threats
Neta Shlezinger, PhD, Ass. Professor, The Hebrew University of Jerusalem, Ergosterol as a Driver of Antifungal Resistance and Fungal Virulence
No Time to Wait: Speeding Up Diagnostic Processes
| Plenary Investors Panel: Biotech Investing in a New Reality: What Gets Funded, What Doesn’t, and Why?
Moderator
Mati Gill, CEO, AION Labs
Panelists
Michel Habib, Co-Founder, Managing General Partner, ALIVE Israel HealthTech Fund
Raphaël Wisniewski, Partner, Andera Partners
Michal Geva, Managing Partner & Co-Founder, Triventures
Ittai Harel, Managing Partner, Pitango Venture Capital
Shahar Tzafrir, Managing Partner, TLV Partners
Michelle Lynn-Hall, PhD, Co-Founder and General Partner, Entrée Bioventures
Michael Rice, Founding Partner, LifeSci Advisors
Prof. Itzhak Fried, MD, Professor of Neurosurgery and Head of Applied Brain Research Center, UCLA & the Reichman University | The Brain at a Turning Point: Repair, Decode, and Reimagine
Dror Bin, CEO, Israel Innovation Authority
HALL A
Beyond NeuroPharma and NeuroTech: Integrated Brain Control
Moderators
Iris Grossman, PhD, Chief Therapeutics Officer, Eleven Therapeutics
Prof. Itzhak Fried, MD, PhD, Professor of Neurosurgery, UCLA, Head of the Applied Brain Research Center, Reichman University
Keynote Speakers
Israeli Success Story Elizabeth Kogan, CEO & Co-founder, Syremis Therapeutics
MedTech Emerging Science and Solutions
Prof. Teodoro Forcht Dagi, MD, MPH, Neurosurgeon & Professor, Professor of Neurosurgery at the Mayo Clinic, USA. Professor at Queen’s University Belfast, UK. Professor at CURAM, the medical device consortium at the National University of Ireland. Professor at the University of Galway, Ireland. Chairman of Indoma Care, USA.
Market Global Trends
Mayan Katz, Partner, Goodwin Procter LLP, NeuroHealth – Market Trends, Challenges, and Integrated Approach
Company Presenters
Talia Cohen Solal, CEO, NeuroKaire, From Detection to Prediction: Diagnosing Disease Before Symptoms
Dr. Yotam Eldar, MD, Co-Founder & CEO, Modulight.Bio, A high-resolution system requires high-resolution tools – Translational Optogenetics ushers a new era of precision
Aharon Grossman, COO, Inner Cosmos Digital Pill for Treatment Resistant Depression
Shiran Zimri, PhD, VP of R&D and Country Lead, Canada, NeuroSense Therapeutics, From Idea to Impact: The Scientific Journey of PrimeC Toward Phase 3 in ALS
Eliav Shaked, Co-Founder & CEO, RetiSpec, Healthcare from the Eye: AI-Powered Eye Exams for Early Alzheimer’s Detection
Dori Pelled, PhD, CEO, B Sense-Bio, BSEN760:A Novel, Oral, First-In-Class, Non-Opioid Approach to Treat Chronic Pain
Michael Zilbershlag, Co-Founder & CEO, Exodus Technology, Ultrasound-mediated nanoparticles for targeted painful nerve ablation – preclinical validation
HALL B
Engineering the Beating System: Biology Meets Technology
Moderators
Opening Remarks
Prof. Chaim Lotan, MD, Director, Heart Institute, Chief Innovation Officer, Hadassah, Hebrew University
Gilad Glick, Vice President, Venture Investments, MedTech, JJDC
Keynote Speakers
Dr. Peter J. Fitzgerald, MD, PHD, Professor Emeritus, Department of Medicine (Cardiology), Stanford University, How can AI Accelerate and Optimise the Innovation Process?
Christopher Picariello, President of Johnson & Johnson Innovation – JJDC Inc. (JJDC), JJDC Focus on Cardiology. What do we see in MedTech AI?
Daniel. M. Goldstein, PhD, Advocate and Patent Attorney, Sanford T. Colb & Co, What Happens if ChatGPT is the Co-Inventor of a Prosthetic Valve?
Company Presenters
Shai Elbaz, PhD, CEO, Spinodal, Transcatheter Microfluidic Robotic Shaping and Navigation
Technology
Shuki Porath, CEO, PhysioMap, Mapping the Unmapped: Patient-Specific AF Diagnostics to Guide Precision Therapy
Eyal Sandach, CEO, Quintra Medical, Curing the Incurable; Pioneering the First Curative Approach to Prevent Sudden Cardiac Death Due to Brugada Syndrome
Rotem Kaynan, CEO, Curespec Changing the Paradigm: Non-Invasive Renal Therapy for Hypertension
Eitan Kyiet, Co-CEO, CardiacSense, Cuffless, calibration-free blood pressure measurement powered by AI and a unique anatomical model
Questions and Discussion
HALL C
Rewriting Biology in Vivo: The Age of Cellular Reprogramming – The Next Frontiers in Genetic Medicine
Moderator
Christian Dombrowski, PhD, Senior Vice President, Averna Therapeutics
Keynote Speakers
Michelle Lynn-Hall, PhD, Co-Founder and General Partner, Entrée Bioventures
Christian Dombrowski, PhD, Senior Vice President, Averna Therapeutics, In Vivo Cellular Reprograming: An Overview
Company Presenters
Ronen Eavri, CEO, Barcode Nanotech, Barcoded AI-Guided Nanoparticles for Precision RNA Delivery
Dror Melamed, President & CTO, MetaboCure, MetaboCure – Restoring Life to Cancer Cachexia Patients
Yifat Ofir-Birin, Senior Director & Director of Experimental Biology, Averna Therapeutics, An all-RNA platform for safe-harbor gene insertion
Dr. Tali Stauber. MD, Scientific Co-Founder, Zelig Therapeutics, From symptoms control to Cure: Resetting Allergy with mRNA CAR-T therapy
Roy Mashiach, PhD, Site Manager, RiboX Therapeutics, tLNP-circular RNA in vivo CAR for treatment of autoimmune diseases
Noam Diamant, PhD, Co-Founder & CEO, NOGA Therapeutics Building an In Vivo HSC Gene Therapy Platform, Starting with XLA
HALL A
Redefining the Fight Against Cancer: New Targets, New Modalities
Moderator
Prof. Amnon Peled, Director of the Gene Therapy Institute, Hadassah – Hebrew University Medical Center
Keynote
Beni Surpin, Partner, Goodwin Procter LLP. Winning in an Era of Choice: The New Economics of Oncology.
Prof. Gal Merkel, MD, PhD, MBA, Director, The Davidoff Cancer Center, Founder & Chairmen, Samueli Cancer Institute, Deputy CEO, Rabin Medical Center, Professor, Faculty of Medicine, Tel Aviv University
Company Presenters
Eran Ophir, PhD, CEO, Compugen, From Code to Cure: Compugen’s Novel Cancer Immunotherapy Pipeline Derived from its AI/ML-Powered Computational Platform
Pini Tsukerman, PhD, Founder, CSO, Nectin Therapeutics, Advancing Antibody–Drug Conjugates for Unmet Needs in Oncology
Gil Efron, CEO, Purple Biotech, Purple Biotech: Advancing Next-Generation Multi-Specific Immunotherapies in Oncology
Tomer Cohen, Chief Financial Officer & Chief Business Officer, Kahr Medical LTD, DSP107 – Turning the Promise of Immunotherapy into a Reality for Colorectal Cancer Patients
Ronen Segal, CTO, Alpha Tau Medical, Localized, Systemic and Safe? The Alpha DaRT – New Radiotherapeutics which Refines Treatment in Solid Tumors
Peter Siman, PhD, CEO, Intra-Gel LTD, From ineligibility to opportunity: long-acting intratumoral cisplatin in unresectable head and neck cancer
Sarit Batsir, PhD, CEO, Dio Tree First-in-class DIO3 inhibitor as a novel treatment strategy in ovarian cancer
Concluding Remarks
HALL B
How AI Is Rewiring Pharma R&D: From Molecules to Models to Quantum Technology
Moderators
Dr. Karin Noy, PhD, External Science Lead AI Discovery & Early Development, Pfizer
Yael Gruenbaum-Cohen, DMD, PhD, General Partner, Entree Bioventure
Keynote Speakers
Yuval Dvir, Head of Scaled Partnerships, Google Cloud, The Walls Were Always Artificial: How AI Dissolves the Silos Between Disciplines and Functions
Eran Harary, SVP, Clinical Development, R&D, Teva: Rewriting Drug Development: The AI and Quantum Inflection Point, and the Human Factor
Miriam Shtilman, Venture Capital Partner, Tal-Ventures
Company Presenters
Yanay Ofran, CEO, Biolojic, Design, AI-Designed Multi-Specific ADCs in Standard IgG Format
Denovai
Dov Gertz, CEO, Converge Bio Introducing ConvergeAB: A Generative AI Platform for Antibody Optimization
Noam Katz, PhD, Co-Founder, CombinAbleAI, Bridging Platforms: The Strategic Integration of CombinAble and insitro in AI-Driven Biologics
Discovery
Tom Shani, CEO, Pro-Phet Redefining Drug Discovery — From Sequence to Novel Chemical Space
Amit Bleiweiss, Senior Data Scientist, Gen AI & LLMs, NVDIA
Eran Seger, CEO, Protai Unlocking the Therapeutic Potential of Protein Complexes with the Power of Structural Proteomics and AI
Sigal Kalmanson Cusnir, CEO, Starget Pharma, Lights Will Guide You: AI-Driven Radioligands in the Darkness of Cancer
Panel Discussion
What makes an AI & Quantum biotech company valuable (investable, transforming drug development, etc.?
Ran Achituv, Managing Partner, Entree Capital
Yair Benita, CTO, AION Labs
Renana Ashkenazi, Managing Partner, Grove Ventures
Miriam Shtilman, Venture Capital Partner, Tal-Ventures
Gali Dolev Golan, AI Strategy Lead, Pfizer
HALL C
Reinventing Clinical Trials: New Models, Technologies and Companies
Moderator
Ittai Harel, Managing Partner, Pitango Venture Capital
Introduction
Ittai Harel, Managing Partner, Pitango Venture Capital
Keynote Speaker
State of the Union; Clinical Trials
Dikla Shpangental, General Manager &, Israel and Global Account Director, IQVIA, Global Clinical R&D at an Inflection Point: Productivity, Technology, and the
Path Forward
Company Presenters
Iddo Peleg, CEO & Co-Founder Yonalink, (acquired by Veeva) The Yonalink Experience: Navigating the Path from Founding to Acquisition
Dan Goldstaub, PhD, Co-Founder, PhaseV, From Protocol to Execution: Navigating Clinical Complexity with End-to-End AI
Tzvia Bader, Co-Founder & CEO, Leal Health (now merged with Nexus Precision) Revolutionizing Cancer Care: How Generative AI is Transforming Treatment Access and Optimization
Orr Inbar, Co-Founder & CEO, QuantHealth
Avi Viedman, Co-Founder & CEO, Nucleai
Noam Solomon, Co-Founder & CEO, Immunai, Augmenting Clinical Trials with Deep Immune Profiling and Explainable AI
Edmund Ben-Ami, Co-Founder & CEO, NeuraLight Brain Health Enters the Precision Medicine Era: NeuraLight Drives the Next Revolution in Neurology Drug Development
Panel
Moderator: Ittai Harel, Managing Partner, Pitango HealthTech
Participants:
Dikla Shpangental, Senior VP & GM SISA, IQVIA
Noam Solomon, Co-Founder & CEO, ImmunAI
Orr Inbar, Co-Founder & CEO, Quanthealth
Dan Goldstaub , Co-Founder, Phase V
Iddo Peleg, ex CEO of Yonalink, now SVP Strategy, Site Solutions, Clinical Trials, Veeva Systems
Avi Veidman, Co-Founder & CEO Nucleai
Raanan Berger MD, Director, Jusidman Cancer Center, Sheba
Panel focus
”Opportunity is huge, but change is hard… we’ll discuss what it’s been like to introduce innovations to the core of pharma, to CROs to biotechs, what works and what does not? How have you been contending? Opportunities and vision as seen from start-ups eyes, and from CROs / clinical trial operators’ eyes”
Christopher Picariello, President of Johnson & Johnson Innovation – JJDC, Inc. (JJDC)
Prof. Ben Reis, Computational Health Informatics Program, Harvard Medical School and the Boston Children’s Hospital, Predictive Medicine in the Age of AI
Genomics Meets AI: From Data to Decisions
Prof. Dror Harats, MD, CEO, ImmuneWalk Therapeutics
Prof. Gidon Rechavi, MD PhD, Founding Director, Cancer Research Center, Sheba Medical Center, Professor of Pediatrics and Human Molecular Genetics, Tel Aviv University
Ariel Larey, AI Research Scientist, NVIDIA
HALL A
Restoring Vision: Where Biology Meets Engineering
Moderator
Prof. Anat Loewenstein, MD, President of the Israeli Ophthalmological Society, Dean of the Faculty of Medicine, Chairperson of Ophthalmology, Tel Aviv University, Sourasky Medical Center
Dr. Barak Azmon, MD, Director, Pres-By
Prof. Itay Chowers, MD, Professor of Ophthalmology & Chairman at the Division of Ophthalmology, Hadassah – Hebrew University Medical Center
Company Presenter
Aryeh Batt, CEO & Co-Founder, Precise Bio, 3D Bio Printed Tissues-From Science to the Clinic – Initial Clinical Data
Alex Shur, Vision R&D Director, Shamir Optical Industry, Where Vision Science Meets Driving
Ran Yam, CEO & Co-Founder, NovaSight, TrackSight-Eye-Tracking Based Myopia Digital Prevention
Liz Risenberg , AVP head of Vision Business, Lumenis, Innovation in Vision Care
Guy Oren, CTO, VISION6 Focus on Innovation – The OPIRA accommodating IOL
Marc Abitbol, PhD, CEO, Visionix From a Small Caravan to an International Group; or how to Transform Healthcare Process
Nir Betser, CEO, ABLE Therapeutics, Topical Retinal & Corneal Effective Treatments
HALL B
AI as an Equalizer: From Center to Periphery in Healthcare
Moderator
Avner Halperin, CEO, Sheba Impact
Keynote Speakers
Dr. Galia Barkai, MD, Founder, Sheba BEYOND
Esti Shelly, Director of the Digital Health Division, Israel Ministry of Health
Company Presenters
Mira-Altmark-Sofer, VP Marketing, Pulsenmore
Pinny Chaviv, Co-Founder, Ikko Health Breaking Paradigms in Medical Imaging – availability, cost and use cases
Amit Aharoni, VP of Strategy & Business Development, AISAP
Hanna Ben-Yehuda, CEO & Co-Founder, CommU When Patients and Clinicians Don’t Speak the Same Language – CommU: a Real-Time AI Medical Interpretation
Roy Rabinowitz, Ph.D, Co-Founder & CEO, Kanso Diagnostics
Ziv Yekutieli, CEO, Mon4t
Yael Shtirit, COO, DreaMed Diabetes
HALL C
Shaping the Future of Personalized Nutrition: Evidence-Driven Science Meets Real-World
Moderator
Tammy Meiron, PhD, CTO, Fresh Start FoodTech Incubator
Keynotes
Prof. Iris Shai, Dean- Sustainability, Reichman University, Chair- Nutrition Center, Ben
Gurion University & Adjunct Professor, Harvard University, Precision nutrition, Omics & Dietary RCTs
Prof. Vered Padler-Karavani, Associate Professor. Dept. of Cell Research &
Immunology, Center for Nanoscience and Nanotechnology, The George S. Wise
Faculty of Life Sciences, Tel Aviv University, Assessing Neu5Gc Disease Risk: A Novel Diagnostic and
Dietary Management Tool
Maya Elhalal, Founder & CEO, Longevity Lab, From Diet Trends to Longevity Strategy: Building Evidence-Driven Nutrition That Actually Works
Company Presenters and PhD Students Presentations
Oded Skaliter, PhD, Co-founder & CT, CapsiBreed
Hilla Ben Hamo, PhD, Co-Founder & CEO, MeNow, Designing What We Eat: Nutrition
Ingredients in the Age of AI
Si Naftaly, Co-Founder & CTO, Milkosome, Harnessing Milk to Unlock Oral Effective Delivery
Eden Beck, M.Sc. Candidate in Biotechnology & Food Engineering, Technion, Assessing the
Bio Accessibility of Cultured Meat and Jellyfish as Emerging Proteins
Sivan Isaschar-Ovdat, Ph.D.: Food R&D & CTO Innovation Manager at Tami Imi, ICL
Group: Digestibility Matters: When Models Drive Mineral Conclusions
HALL C
Moderators
Anat Naschitz, Managing Partner, 9vc
Reut Shema, Partner, aMoon Fund
Judges
Yair Benita, CTO, AION Labs
Amir Blatt, Principal, JJDC
Neta-li Feuerstein-Ganor, Medical and Regulatory Affairs Director, Eli Lilly Israel
Yael Grunberg-Cohen, General Partner, Entree Bio Ventures
Peter Kash, Chairman, Camelot BioCapital
Joe Korff, Founder, The Arc Companies
Adar Makovski-Silverstein, Principal, Arkin BioVentures
Anat Naschitz, Managing Partner, 9vc
Reut Shema, Partner, aMoon
Irit Yaniv, Founding Partner & Chairperson, Almeda Ventures
